The Cystic Fibrosis Center at CWRU conducts translational research, with preclinical and clinical research projects that utilize a number of coe facilities. This application requests funds for 5 biomedical research cores, an administrative component and 2 pilot and feasibility projects. The cores include an internationally utilized 1. Mouse Models Core that provides mice and relevant assays for in vivo studies;2) a Bioanalyte Core to measure a range of molecules routinely analyzed by investigators;3) a Clinical Studies Core to facilitate clinical research projects;4) a Biostatistics and Bioinformatics Core to accommodate the evolving and increasing statistical and computations needs of Center investigators, and 5) a Rodent Imaging Core to provide in vivo monitoring for various studies. The purpose of these cores, administrative and feasibility components are:1) to provide researchers with state of the art core facilities and necessary reagents to optimize and improve the throughput of their CF-related research while maintaining or improving the quality of studies by providing centralized services. This goal is realized by the Biomedical Research Cores. 2) to provide a centralized resource for coordinating activities of the CF Center, including allocation o pilot and feasibility awards, an enrichment program and interaction with other institutional resources (other cores, CTSA, etc.). This goal will be addressed by the Administrative Component and executive committee. 3) to bring research discoveries to the clinic. Our CF Center has a long track record implementing this goal and proposes to continue to do so, capitalizing on new and exciting developments from within our Center as well as through collaborations with outside investigators. This goal is facilitated by the Biomedical Research Cores, with specific emphasis on the Clinical Studies Core. 4) to provide training and mentoring in CF-related research for students and fellows embarking on research projects, as well as investigators pursuing new avenues of research. This goal is also a function of the Biomedical Research Cores.
Core facilities and infrastructural support have expedited CF research and reduced costs while accelerating the processes of moving science to therapy. The cores described in this application are all relevant to improving our understanding of cystic fibrosis and using that information to develop and improve therapies.
|Bruscia, Emanuela M; Bonfield, Tracey L (2016) Cystic Fibrosis Lung Immunity: The Role of the Macrophage. J Innate Immun 8:550-563|
|Jiang, Kai; Jiao, Sen; Vitko, Megan et al. (2016) The impact of Cystic Fibrosis Transmembrane Regulator Disruption on cardiac function and stress response. J Cyst Fibros 15:34-42|
|VanDevanter, Donald R; Morris, Nathan J; Konstan, Michael W (2016) IV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosis. J Cyst Fibros 15:372-9|
|VanDevanter, D R; Flume, P A; Morris, N et al. (2016) Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosis. J Cyst Fibros 15:783-790|
|Than, B L N; Linnekamp, J F; Starr, T K et al. (2016) CFTR is a tumor suppressor gene in murine and human intestinal cancer. Oncogene 35:4179-87|
|Hsu, Daniel; Taylor, Patricia; Fletcher, Dave et al. (2016) Interleukin-17 Pathophysiology and Therapeutic Intervention in Cystic Fibrosis Lung Infection and Inflammation. Infect Immun 84:2410-21|
|VanDevanter, Donald R; Pasta, David J; Konstan, Michael W (2015) Treatment and demographic factors affecting time to next pulmonary exacerbation in cystic fibrosis. J Cyst Fibros 14:763-9|
|Donnola, Shannon B; Dasenbrook, Elliott C; Weaver, David et al. (2015) Preliminary comparison of normalized T1 and non-contrast perfusion MRI assessments of regional lung disease in cystic fibrosis patients. J Cyst Fibros :|
|Powers, Scott W; Stark, Lori J; Chamberlin, Leigh A et al. (2015) Behavioral and nutritional treatment for preschool-aged children with cystic fibrosis: a randomized clinical trial. JAMA Pediatr 169:e150636|
|Sagel, Scott D; Thompson, Valeria; Chmiel, James F et al. (2015) Effect of treatment of cystic fibrosis pulmonary exacerbations on systemic inflammation. Ann Am Thorac Soc 12:708-17|
Showing the most recent 10 out of 417 publications